Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04416451 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
A Phase 2 study of Marginal Zone Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 8
- Study locations
NCT04416451 is a Phase 2 study of Marginal Zone Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 103-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT04416451, a Phase 2 study of Marginal Zone Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Rituximab
Study Locations (8)
New York
- Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Rockville Centre (All Protocol Activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (All protocol Activities) - Montvale
California
- City of Hope Cancer Center (Data collection only) - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04416451
The ClinicalTrials.gov registry entry for NCT04416451 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (94% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT04416451 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT04416451 about?
NCT04416451 is a clinical study titled "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma". This study will help researchers understand how effective the combination of venetoclax and rituximab is in treating MZL in people who have not received a previous treatment for their cancer.
What is the current status of trial NCT04416451?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-05-04. Estimated completion is 2026-06.
What conditions does trial NCT04416451 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma.
What interventions are being tested in trial NCT04416451?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT04416451?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04416451 being conducted?
This trial has 8 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.